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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
Polidocanol foam sclerotherapy is effective in treating varicose veins as compared to conventional 
treatments. 
STUDY DESIGN: Review of three randomized controlled trials. All three studies are published 
in English between 2008 – 2012. 
DATA SOURCES: Three randomized control trials were found using PubMED and Medline. The 
sources were selected based on the outcomes measured and how the studies and outcomes mattered 
to patients (POEMS). 
OUTCOMES MEASURED: The patients’ assessment for quality of life analyzed by logistic 
regression model, Chronic Venous Insufficiency Questionnaire (CVIQ), EQ-5D model, Visual 
analog scale and Venous clinical severity score (VCSS) and ordinal scale. 
RESULTS: Three randomized controlled trials were included in the review. The first study, Rabe 
et al study showed statistically significant evidence in patient satisfaction (p= 0.008) in reduction 
of symptoms of varicose veins among the polidocanol foam sclerotherapy group as compared to 
liquid treatment. The second study Shadid et al showed that patient satisfaction of venous 
symptoms was higher in surgical intervention group (66.1%) as compared to the polidocanol foam 
sclerotherapy group (59.6%). However, when other factors like cost and cosmetic evidence of 
scars were considered; polidocanol foam sclerotherapy reflected as a better option. The third study, 
Ukritmanoroat demonstrates that polidocanol foam sclerotherapy has greater efficacy for venous 
sclerosis and venous symptoms as compared to polidocanol liquid therapy (p=0.002).  
CONCLUSION: The systemic review concludes that polidocanol foam sclerotherapy is an 
effective treatment in treating varicose veins. When compared to different conventional 
treatments; there are different factors like cost, quality of life post treatment, cosmetic effects of 
individual treatments that should also be considered when considering the efficacy of the 
Polidocanol foam sclerotherapy. 
KEY WORDS: Polidocanol foam sclerotherapy, varicose veins.  
 
  
INTRODUCTION 
Chronic venous disease has often not been highlighted and it goes unnoticed in the medical 
field by primary and cardiovascular health care providers because of an under representation of 
how big the impact and magnitude of the problem on patient lifestyle. There are a lot of people 
affected by chronic venous disease and the importance of the disease is directly related to the 
number and the socioeconomic impact of the more severe complications.1 Lower Extremity venous 
disease is a very common vascular disorder seen in people as they get older. Chronic venous 
disease is classified by the presence of morphological (venous dilation) or functional (venous 
reflux) abnormalities in the veins due to venous insufficiency. The initial clinical presentation of 
the disease is highly variable and the most common symptoms consist of lower extremity pain or 
discomfort. Moreover, some of the physical findings include abnormal venous dilation such as 
telangiectasia, varicose veins, edema, inflammation, dermatitis, or ulceration.1,2 Moreover, venous 
insufficiency is also associated with chronic disability, diminished quality of life, and high health 
care costs. It is seen that periods of high venous pressure due to prolonged standing or heavy lifting 
are major contributing factors. The highest incidence is seen in women post-partum. The 
superficial veins are most commonly involved, typically the great saphenous vein.3,4 The standard 
treatment used in treating varicose veins was surgical stripping of the vein. However, this paper 
evaluates three randomized control trials (RCTs) comparing the safety, and efficacy of Polidocanol 
foam sclerotherapy with other conventional interventions like liquid treatment or surgical 
interventions. 
 LE venous insufficiency is a common health problem in Western countries. Varicose veins 
are very prevalent in the adult population with an estimated prevalence between 5% to 30%, with 
a female to male majority of 3:1.4 The Framingham Heart Study, found an annual incidence rate 
of 2.6% in women and 1.9% in men.5 The disease has a substantial impact on quality of life, 
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resources and budgets of healthcare systems. However, the exact cost of treatment of VV is not 
known; the use of surgery and other interventions cost approximately $2,500 for each patient. 4 As 
per Eberhardt et al1, in the year 2002-03, 51,456 of hospital consultant episodes were for VV of 
LE. Of those consultant episodes 98% required hospital admissions. Moreover, serious 
complications of venous insufficiency like venous ulcers cost more than $3 billion yearly in US.1  
Inadequate muscle pump function, incompetent venous valves (reflux), and venous 
thrombosis or obstruction are causes of elevated venous pressure.5 The risk factors include 
advancing age, family history of venous disease, ligamentous laxity, prolonged standing, increased 
BMI and pregnancy. The factors responsible for a transition from mild to more severe 
manifestations, and whether or not there is necessarily a sequential progression of the condition, 
are not well known and the treatment varies based on the severity of the condition. For mild 
symptoms compression stockings are helpful. However, for more severe form of the disease, 
different conventional therapies are used such as liquid sclerotherapy, surgical intervention, 
surface laser therapy, electrodessication, PIN stripping and ambulatory phlebotomy.4 
All the treatment options mentioned above are effective in treating varicose veins but the 
long-term efficacy and recurrence varies for each patient and is not studied well. The use of 
polidocanol foam sclerotherapy has been shown to be cost-effective and less invasive as compared 
to surgery. It also has a shorter recovery period as compared to the surgical and other interventions. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not Polidocanol 
foam sclerotherapy is effective in treating varicose veins as compared to conventional treatments? 
 
 
Patel, Polidocanol Foam and Varicose Veins  3 
 
METHODS 
 All three studies were randomized controlled trials (RCTs) that evaluated Polidocanol foam 
sclerotherapy as an effective treatment for treating varicose veins as compared to other 
conventional interventions. The three studies included in this review used specific criteria for 
selection of studies. The population included men and women with symptomatic varicose veins 
over the age of 18 years. All studies excluded any patients with a history of Deep vein thrombosis, 
venous ulcer, severe arterial hypertension, patients being treated with anti-coagulation 
medications. 
 The intervention used in all three studies was Polidocanol foam sclerotherapy. The 
treatment group was compared to the control groups who were given other conventional 
interventions such as Polidocanol liquid treatment or surgery interventions. The outcomes 
measured were safety, efficacy, quality of life and patient satisfaction of polidocanol foam 
sclerotherapy in treating varicose veins. 
 Keywords used when searching for articles consisted of varicose veins, polidocanol, foam 
sclerotherapy. All the articles were in English and in peer-reviewed journals. The articles were 
researched by the author and obtained through PubMed and Medline. The articles were selected 
based on the types of studies, its relevance to the clinical question being asked and the patient 
oriented outcomes (POEMS). The statistics that were utilized and reported included p-value, 
relative benefit increase (RBI), absolute benefit increase (ABI) and numbers needed to treat 
(NNT). Table 1 displays the demographics and characteristics included in studies. 
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Table 1 - Demographics & Characteristics of included studies 2,6,7 
Study Type #of 
pts 
Age 
(yrs) 
Inclusion criteria Exclusion criteria W
/D 
Intervention 
Rabe6 
2008 
RCT  101 18-70 - Age of 18 and 
70 yrs with an 
incompetent 
Great Saphenous 
Vein (GSV) with 
a diameter <12 
mm measured 3 
cm below the 
sapheno-femoral 
junction (SFJ) 
- Reflux duration 
of ≥1 second 
measured 3 cm 
below the SFJ 
under Valsalva 
maneuver.  
Patients with a 
history of deep vein 
thrombosis, 
superficial 
thrombosis, major leg 
edema, known patent 
foramen ovale, were 
excluded from the 
trial. 
2 Therapeutic 
treatment 
with 3% 
Polidocanol 
foam vs. 
3% 
Polidocanol 
liquid  
 
Shadid7 
2012 
RCT 460 20-87 - Presence of 1 
or more venous 
symptoms along 
with 
incompetence of 
the SFJ and GSV 
and a reflux time 
>0.5s. 
-Normal deep 
venous system 
on duplex 
imaging. 
-Incompetent deep 
venous system, signs 
of deep vein 
thrombosis on duplex 
imaging. 
-Active ulcer or 
contradiction to the 
use of polidocanol 
26 3% 
Polidocanol 
foam vs. 
surgery 
Ukritma
noroat2 
2011 
RCT 50 19-66 - Patients with 
primary reticular 
varices (>2mm 
of diameter) or 
postoperative 
varices that did 
not involve the 
SFJ. 
Patients with truncal 
varices, post-
thrombotic varices 
with incompetence,  
Chronic ischemia of 
the LE. 
Severe arterial 
hypertension (blood 
pressure >180/95mm 
Hg. 
Patients on anti-
coagulants, anti-
inflammatories 
and/or diuretics  
0 Therapeutic 
treatment 
with 0.5mL 
Polidocanol 
(foam 2mL) 
vs. baseline 
matched 
0.5ml 
polidocanol 
liquid. 
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OUTCOMES MEASURED 
 Study outcomes measured were the safety, efficacy of the treatment and health related 
quality of life of the patients. Outcomes were measured by using different methods. Rabe et al 
measured outcomes using a Chronic Venous Insufficiency Questionnaire (CVIQ) that consisted of 
19 questions and 5 possible answers per question (i.e “not affected”, “somewhat affected”, 
“moderately affected”, “highly affected”, “impossible”) that was completed by the patient 3 
months after the last treatment. CVIQ is a verified tool for measuring quality of life in patients 
with venous disease. These were then analyzed using a logistic regression model and analysis of 
covariance (ANCOVA) scale.6  
 Shadid et al measured outcome based on symptoms reduction, health related quality of life, 
adverse events and direct hospital costs using a EQ-5d method. The evaluations were done at 
baseline, 3 months, 1 year and 2 years after the treatment.  Patients were asked about the presence 
of venous symptoms such as pain, cramps, heavy and restless legs. EQ-5D consists of five 
dimensions (mobility, self-care, usual activities, pain and mood), each of which is rated at three 
levels (no problems, some problems, severe problems) that yields a possibility of 243 combination 
health states. Each health state has a utility score from worst possible (0) to best possible (100).7 
 Ukritmanoroat T., measured treatment safety and efficacy in treating varicose veins and 
venous symptoms such as sclerosis, pain, inflammation, skin pigmentation that was graded on an 
ordinal scale (absent, mild, moderate or severe). The evaluations were done at 13, 30, and 90 days 
by research team other than the doctor who performed the treatment. Analysis was done using chi-
square test or Fishers’ exact test.2 
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RESULTS 
 All the selected articles are randomized controlled trials. In all three articles Polidocanol 
foam sclerotherapy is used as an intervention for treating varicose veins. The p-value was 
significant at p<0.05 in all the trials. Rabe et al6 study comprised of 108 patients with an 
incompetent GSV. The patients were randomized into two groups; Polidocanol foam (55 patients) 
and Polidocanol liquid (53 patients). Of the 108 patients who entered the trial, 2 (1.85%) exited 
the study early due to violation of entry criteria. “Worst-case” analysis was not done on the 
participants that did not complete the trial. The patient’s self-reported assessment of the outcome 
showed that “improved nicely” or “improved excellent” was selected by 36 patients out of the 55 
(66%) who were treated with Polidocanol foam; whereas 22 out of the 53 (42%) patients selected 
that in the Polidocanol liquid group. The patient satisfaction was significantly (p=0.0008) higher 
in the foam group than in the liquid group. Table 2 shows the treatment effects of Polidocanol 
foam sclerotherapy and patient satisfaction. Relative benefit increase (RBI) was calculated to be 
0.57. Absolute benefit increase (ABI) was calculated to be 24%. Numbers needed to treat (NNT) 
was calculated 5 patients, indicating that 5 patients need to be treated with Polidocanol foam rather 
than Polidocanol liquid to see one more patient who had “improved excellently” than compared to 
liquid treatment.6 
Table 2: Treatment effect of Polidocanol foam on varicose veins (Rabe et al) 
CER EER RBI ABI NNT P 
42% 66% 0.57 24% 5 0.0008 
 
 Shadid et al7 study comprised of 430 patients with great saphenous varicose veins. The 
patients were randomized into groups of Polidocanol foam (230) and surgery (200). Of the 430 
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patients who entered the trial, 40 (9.30%) did not continue with the follow-up. “Worst-case” 
analysis was not done on the participants that did not complete the trial. Complete patient 
satisfaction with the reduction in venous complaints was reported by 59.6% of patients in the 
Polidocanol foam group and 66.1% of those having surgery. P-value was 0.207. Table 3 shows the 
treatment effects of Polidocanol foam sclerotherapy and patient satisfaction. Relative benefit 
increase (RBI) was calculated to be -9.8%. Absolute benefit increase (ABI) was calculated to be  
-6.5%. Numbers needed to treat (NNT) was calculated as -15 patients, indicating that for every 15 
patients treated with Polidocanol foam one fewer would have patient satisfaction by the end of 
their treatment as compared to the surgery treatment.7 
Table 3: Treatment effect of Polidocanol foam on varicose veins (Shadid et al) 
CER EER RBI ABI NNT P 
66.1% 59.6% -9.8% -6.5% -15.38*= -15 0.207 
*Outcome measured was efficacy of foam polidocanol sclerotherapy, so this negative value means that for every 15 patients who 
took foam polidocanol sclerotherapy, 1 fewer patient was satisfied as compared to the surgery intervention. 
  
 Ukritmanoroat2 study comprised of 50 patients who had more than 1 varicose vein. Each 
patient received Polidocanol foam at one site and polidocanol liquid treatment at the other site. At 
the end of the trial all subjects who started the trial were accounted for. No losses to follow-up 
were noted. Efficacy of treatment and resolution of varicose vein was evaluated at the end of 90 
days after the treatment and 92% decrease was noted in the Polidocanol foam treated location and 
76% in the liquid treated location. Relative benefit increase (RBI) was calculated to be 21.1%. 
Absolute benefit increase (ABI) was calculated to be 16%. Numbers needed to treat (NNT) was 
calculated 7 patients, indicating that 7 patients need to be treated with Polidocanol foam rather 
than Polidocanol liquid to see one more patient who had “improved excellently” than compared to 
liquid treatment.2 
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CER EER RBI ABI NNT P 
76% 92% 0.21 16% 7 0.002 
 
DISCUSSION 
 This selective evidence based medicine review investigated three randomized controlled 
trials to determine whether Polidocanol foam sclerotherapy is effective in treating varicose veins 
as compared to other conventional treatment. 
 All three trials concluded that when analyzed individually Polidocanol foam is effective in 
treating varicose veins. When the analysis was done in comparing Polidocanol foam to other 
conventional treatment like the liquid and surgical intervention the results varied. It was seen that 
patient satisfaction was significantly higher in Polidocanol foam as compared to the Polidocanol 
liquid. Whereas, Surgical intervention has higher patient satisfaction in reduction of venous 
complaints as compared to Polidocanol foam sclerotherapy. 
 The results of Rabe et al6 study are generalized to adult patients with varicose veins in the 
GSV and SFJ and suggests that Polidocanol foam sclerotherapy is very effective in treating 
varicose veins as compared to liquid intervention. The ABI suggests that 24% of patients receiving 
Polidocanol foam will have improvement in varicose veins when compared to patients receiving 
liquid treatment. Some limitations of this study were not being able to follow a “double-blind” 
protocol due to the mechanism and application of the treatments. Polidocanol foam therapy is 
easily identified on ultrasound due to it being more echogenic as compared to liquid polidocanol.6 
 The results of Shadid et al7 study generalized to adult population with varicose veins in the 
GSV and SFJ. The principal finding was that Polidocanol foam sclerotherapy was not inferior to 
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surgical intervention when reflux associated venous symptoms and patient satisfaction was 
considered as the clinical outcome of interest. Hospital costs were also considerably reduced in the 
foam sclerotherapy group. The ABI of this study was -6.5% which suggests that surgical 
intervention will have more improvement as compared to foam sclerotherapy. The p-value in this 
study was 0.207, suggesting that the results are not statistically significant. Also, when comparing 
other factors like cost and cosmetic effects; surgical intervention as costlier and left bigger scars 
as compared to polidocanol foam which was cheaper, easily applicable and no scars were left on 
the skin. The study had some limitations where blinding was not feasible due to the visible scars 
of post-surgery. However, the analyst assessing the outcome using venous duplex was not involved 
in the study. Other limitation was the high dropout rate (9.30%) which were mainly from the 
surgery group.7 
 Ukritmanoroat2 study is generalized to the adult Thai population and shows that efficacy 
of foam sclerotherapy is higher than that of liquid injection. The p-value was 0.002 and the ABI 
suggests that 16% of patients receiving Polidocanol foam will have improvement in varicose veins 
when compared to patients receiving liquid treatment. The study concludes that polidocanol foam 
sclerotherapy is more effective in treating varicose veins as compared to liquid polidocanol 
treatment. The limitation in the study was the population size (50) and demographic where it was 
confined to only Thai population.2  
CONCLUSION 
 Based on this systemic review and chosen studies, Polidocanol foam sclerotherapy is an 
effective treatment for varicose veins. The efficacy and patient satisfaction is consistent in all three 
trials and suggest that foam therapy is significant as compared to liquid and surgical intervention. 
Patel, Polidocanol Foam and Varicose Veins  10 
 
No serious adverse effects were noted in any of the studies. Some limitations noted were the short 
term follow-ups of the studies used, smaller population size in one of the study and the 
demographic limitation in one of the studies used. For a better research and evaluation of 
treatments for reflux and venous symptoms of recurrent varicose veins, longer follow-up is 
required for definitive conclusions. As factors such as recurrence, long term adverse-effects, 
quality of patient life after treatments can be better assessed in longer studies. 
 Future research should be designed to compare the long term effects of foam sclerotherapy 
as compared to other conventional interventions specifically surgical intervention. 
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